Success Metrics

Clinical Success Rate
66.7%

Based on 6 completed trials

Completion Rate
67%(6/9)
Active Trials
0(0%)
Results Posted
67%(4 trials)
Terminated
3(27%)

Phase Distribution

Ph phase_3
7
64%
Ph phase_1
1
9%
Ph phase_2
2
18%

Phase Distribution

1

Early Stage

2

Mid Stage

7

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
1(10.0%)
Phase 2Efficacy & side effects
2(20.0%)
Phase 3Large-scale testing
7(70.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

6 of 10 finished

Non-Completion Rate

40.0%

4 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(6)
Terminated(4)
Other(1)

Detailed Status

Completed6
Terminated3
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (10.0%)
Phase 22 (20.0%)
Phase 37 (70.0%)

Trials by Status

unknown19%
withdrawn19%
completed655%
terminated327%

Recent Activity

Clinical Trials (11)

Showing 11 of 11 trials
NCT05208866Phase 3

Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who Completed Study PA-ADPKD-303

Terminated
NCT04152837Phase 3

Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease

Terminated
NCT04064346Phase 3

Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease

Terminated
NCT03487913Phase 2

The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease

Completed
NCT03717181

Lixivaptan in a Single Subject With Intractable Pain Due to Polycystic Kidney Disease

Unknown
NCT00660959Phase 3

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subject With Euvolemic Hyponatremia

Completed
NCT00578695Phase 3

THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation

Completed
NCT00876798Phase 3

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia

Completed
NCT01055912Phase 2

Study to Evaluate the Effects of Oral Administration of Lixivaptan in Patients With Congestive Heart Failure

Completed
NCT00675701Phase 1

A Study to Define the ECG Effects of Lixivaptan Compared to Placebo and Moxifloxacin in Healthy Adult Men and Women: A Thorough ECG Study

Completed
NCT00876876Phase 3

International, Multicenter, Open-Label and Randomized Withdrawal Study of Oral Lixivaptan in Heart Failure Patients With Chronic Hyponatremia

Withdrawn

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11